Cytovia ramps up production of NK cells ahead of trials

By The Science Advisory Board staff writers

March 18, 2021 -- Cytovia Therapeutics has signed two agreements for research and development and manufacturing operations to move the company's chimeric antigen receptor (CAR)-natural killer (NK) cells derived from universal induced pluripotent stem cells (iPSCs) toward clinical trials in the fourth quarter of 2021 and its gene edited iPSC CAR-NK cells by 2022.

Under the first agreement with the Accelerator and Bioincubator Lab (ABI-LAB), Cytovia will move into a laboratory space at the ABI-LAB facility in Natick, MA. The company has started recruiting research and development and process development personnel to its team. Cytovia will maintain its existing cell therapy operation with the New York Stem Cell Foundation and antibody good manufacturing practice (GMP) manufacturing with STC Biologics.

The Natick labs will conduct activities for NK cell biology, gene editing, antibody and CAR development, and NK cell pilot manufacturing. The NK cell technology will be directly transferred to larger-scale operations in Puerto Rico.

Under the second agreement, Cytovia has signed a long-term joint manufacturing and operations agreement with BioSciencesCorp in Puerto Rico. This will integrate Cytovia's manufacturing processes within an existing 95,000-sq-ft current GMP (cGMP) facility that includes more than 40,000 sq ft of clean-room and biomanufacturing space. The facility is located in Aguadilla, Puerto Rico. Cytovia will recruit manufacturing personnel beginning in summer 2021.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here